Doç. Dr. Sema Türker

• Brustneubildungen 6 Publikationen
  Quelle: OpenAlex / PubMed MeSHPublikationen ansehen
• Magenneubildungen 5 Publikationen
• Kolorektale Neubildungen 3 Publikationen
• Hirnneubildungen 2 Publikationen
• Hepatozelluläres Karzinom 2 Publikationen
• Lebertumoren 2 Publikationen

Medizinische Interessengebiete, die der Arzt im Profil der Einrichtung selbst angegeben hat. Quelle: medicalpark.com.tr.

Berufserfahrung

• 2010 - 2011Polatlı Duatepe Devlet Hastanesi, İç Hastalıkları Uzmanımedicalpark.com.tr
• 2011 - 2016Marmaris Devlet Hastanesi, İç Hastalıkları Uzmanımedicalpark.com.tr
• 2014 - 2015Gölcük Necati Çelik Devlet Hastanesi, İç Hastalıkları Uzmanımedicalpark.com.tr
• 2016Ankara Eğitim Ve Araştırma Hastanesi, İç Hastalıkları Uzmanımedicalpark.com.tr
• 2016 - 2019Ankara Dışkapı Yıldırım Beyazıt Eğitim Araştırma Hastanesi, Tıbbi Onkoloji Yan Dal Asistanımedicalpark.com.tr
• 2019 - 2021Zonguldak Bülent Ecevit Üniversitesi, Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• 2019 - 2021Zonguldak Atatürk Devlet Hastanesi, Tıbbi Onkoloji Uzmanımedicalpark.com.tr

Ausbildung

• 1998 - 2004Ankara Üniversitesi Tıp Fakültesimedicalpark.com.tr
• 2004 - 2010Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları Uzmanlığımedicalpark.com.tr
• 2016 - 2019Ankara Dış Kapı Yıldırım Beyazıt Eğitim Araştırma Hastanesi, Tıbbi Onkoloji Uzmanlığı,medicalpark.com.tr

• FachgebietMedizinische Onkologiemedicalpark.com.trAus der Quelle
• Abteilungsname in der QuelleMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trAus der Quelle
• EinrichtungMedical Park Göztepemedicalpark.com.trAus der Quelle
• ArbeitsschwerpunktBrustneubildungenAus 6 Publikationen ermittelt · Modellversion —Aus der Quelle
• Publikationen48 PublikationenOpenAlexAus der Quelle
• ORCID0000-0001-9040-7266ORCIDAus der Quelle
• Letzte Synchronisierung4. November 2026 20:34https://www.medicalpark.com.tr/hekimler/sema-turkermedicalpark.com.tr

1. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Therapeutic Advances in Medical Oncology, 2026

   DOI 10.1177/17588359261430583 PMID 41835339 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

2. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

   Journal of Clinical Medicine, 2026

   DOI 10.3390/jcm15041657 PMID 41753346 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

3. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

   BMC Cancer, 2026

   DOI 10.1186/s12885-026-15725-9 PMID 41691201 Frei zugänglicher VolltextQuelle: OpenAlex

4. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

   Current Oncology, 2025

   DOI 10.3390/curroncol32110639 PMID 41294701 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

5. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

   Scientific Reports, 2025

   DOI 10.1038/s41598-025-19899-3 PMID 41102268 Frei zugänglicher VolltextQuelle: OpenAlex

6. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

   Journal of Chemotherapy, 2024

   DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 Zitation (Europe PMC) Quelle: OpenAlex

7. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

   Journal of Chemotherapy, 2024

   DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 Zitationen (Europe PMC) Quelle: OpenAlex

8. Systemic Treatment of Esophageal Cancer

   Springer eBooks, 2024

   DOI 10.1007/978-3-031-47024-0_45 Quelle: OpenAlex

9. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

   BMC Cancer, 2023

   DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

10. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

    Journal of Geriatric Oncology, 2023

    DOI 10.1016/j.jgo.2023.101604 PMID 37683369 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex